Everest Medicines Ltd. (HK:1952) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Everest Medicines Ltd. has announced a change in auditors, with PricewaterhouseCoopers resigning and Ernst & Young stepping in from November 15, 2024. The shift aims to enhance cost-effectiveness and maintain strong corporate governance, as the company was unable to agree on remuneration terms with PwC for the upcoming fiscal year. This strategic move is expected to benefit the company and its shareholders.
For further insights into HK:1952 stock, check out TipRanks’ Stock Analysis page.